WO2017018641A8 - 인슐린 수용체 압타머 및 이를 포함하는 약학적 조성물 - Google Patents

인슐린 수용체 압타머 및 이를 포함하는 약학적 조성물 Download PDF

Info

Publication number
WO2017018641A8
WO2017018641A8 PCT/KR2016/004665 KR2016004665W WO2017018641A8 WO 2017018641 A8 WO2017018641 A8 WO 2017018641A8 KR 2016004665 W KR2016004665 W KR 2016004665W WO 2017018641 A8 WO2017018641 A8 WO 2017018641A8
Authority
WO
WIPO (PCT)
Prior art keywords
insulin receptor
pharmaceutical composition
same
composition containing
diabetes
Prior art date
Application number
PCT/KR2016/004665
Other languages
English (en)
French (fr)
Other versions
WO2017018641A1 (ko
Inventor
류성호
윤나오
임종훈
고아라
오은주
박세훈
이지윤
장승기
한승민
김윤동
안나래
Original Assignee
주식회사 포스코
포항공과대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 포스코, 포항공과대학교 산학협력단 filed Critical 주식회사 포스코
Priority to EP16830674.4A priority Critical patent/EP3330379B1/en
Priority to ES16830674T priority patent/ES2899917T3/es
Priority to US15/746,654 priority patent/US10724039B2/en
Priority to JP2018503571A priority patent/JP6514825B2/ja
Publication of WO2017018641A1 publication Critical patent/WO2017018641A1/ko
Publication of WO2017018641A8 publication Critical patent/WO2017018641A8/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

본 발명은 인슐린 수용체에 특이적으로 결합하는 DNA 압타머, 이를 유효성분으로 함유하는 당뇨병 치료용 조성물 및 당뇨병 진단용 조성물에 관한 것으로, 상기 압타머는 기존의 인슐린과 다른 결합 기작을 가짐으로써 암발병률 증가 및 죽상동맥경화와 같은 인슐린에 의한 부작용 보다 효과적으로 당뇨병을 치료하고 진단할 수 있는 것을 특징으로 한다.
PCT/KR2016/004665 2015-07-27 2016-05-03 인슐린 수용체 압타머 및 이를 포함하는 약학적 조성물 WO2017018641A1 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP16830674.4A EP3330379B1 (en) 2015-07-27 2016-05-03 Aptamer against insulin receptor and pharmaceutical composition containing the same
ES16830674T ES2899917T3 (es) 2015-07-27 2016-05-03 Aptámero contra el receptor de insulina y la composición farmacéutica que lo contiene
US15/746,654 US10724039B2 (en) 2015-07-27 2016-05-03 Aptamer against insulin receptor and pharmaceutical compostion containing the same
JP2018503571A JP6514825B2 (ja) 2015-07-27 2016-05-03 インスリン受容体アプタマーおよびこれを含む薬学的組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0106151 2015-07-27
KR20150106151 2015-07-27

Publications (2)

Publication Number Publication Date
WO2017018641A1 WO2017018641A1 (ko) 2017-02-02
WO2017018641A8 true WO2017018641A8 (ko) 2017-03-02

Family

ID=57885164

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/004665 WO2017018641A1 (ko) 2015-07-27 2016-05-03 인슐린 수용체 압타머 및 이를 포함하는 약학적 조성물

Country Status (6)

Country Link
US (1) US10724039B2 (ko)
EP (1) EP3330379B1 (ko)
JP (1) JP6514825B2 (ko)
KR (1) KR101881500B1 (ko)
ES (1) ES2899917T3 (ko)
WO (1) WO2017018641A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230159934A1 (en) * 2018-05-10 2023-05-25 Aptamer Sciences Inc. Insulin receptor aptamer and pharmaceutical composition for treating diabetes comprising the same
KR102218267B1 (ko) * 2018-10-15 2021-02-23 한양대학교 산학협력단 성상교세포 특이적 핵산 압타머 및 이의 용도
WO2021201516A1 (ko) * 2020-03-30 2021-10-07 주식회사 압타머사이언스 인슐린 수용체 특이적 압타머 및 이의 용도
CN113549623B (zh) * 2021-05-31 2023-07-11 武汉维尔博生物科技有限公司 一种同时检测胰岛素与葡萄糖的适配体组合、检测传感器及其制备方法
KR20230131326A (ko) * 2022-03-03 2023-09-13 주식회사 압타머사이언스 인슐린 수용체 특이적 압타머 및 이의 이용
WO2024005240A1 (ko) * 2022-06-30 2024-01-04 포항공과대학교 산학협력단 인슐린 수용체 결합 압타머 이량체 및 이의 용도
KR20240053520A (ko) * 2022-10-14 2024-04-24 포항공과대학교 산학협력단 Igf-1 수용체 결합 압타머 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003261264B2 (en) * 2002-07-25 2008-12-11 Archemix Corp. Regulated aptamer therapeutics
US20100076060A1 (en) * 2005-09-15 2010-03-25 Duke University Aptamers as agonists
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US20130059292A1 (en) 2011-08-30 2013-03-07 Aptamer Sciences Inc. Method of detecting a target using aptamer-mediated protein precipitation assay

Also Published As

Publication number Publication date
WO2017018641A1 (ko) 2017-02-02
KR20170013178A (ko) 2017-02-06
US20190032060A1 (en) 2019-01-31
KR101881500B1 (ko) 2018-07-24
ES2899917T3 (es) 2022-03-15
EP3330379A4 (en) 2019-01-02
EP3330379A9 (en) 2018-07-18
EP3330379B1 (en) 2021-10-27
JP6514825B2 (ja) 2019-05-15
JP2018530994A (ja) 2018-10-25
US10724039B2 (en) 2020-07-28
EP3330379A1 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
WO2017018641A8 (ko) 인슐린 수용체 압타머 및 이를 포함하는 약학적 조성물
EP3315608A4 (en) Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
EP3895717A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING WEISSELLA CIBARIA WIKIM28 AS ACTIVE SUBSTANCE
WO2014097151A3 (en) Autotaxin inhibitors
PH12016501724A1 (en) Isoindolinone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
EP3359193A4 (en) Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
WO2015066426A3 (en) Angiopoietin-based interventions for treating cerebral malaria
RS62666B1 (sr) Farmaceutska kompozicija za lokalnu primenu koja sadrži barem amitriptilin za lečenje perifernih neuropatskih bolova
EP3266317A4 (en) Composition for preventing, improving or treating neurological disorders, containing osmotin peptide as active ingredient
EP3597208A4 (en) PHARMACEUTICAL COMPOSITION WITH ATPIF1 FOR THE TREATMENT OF DIABETES
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
EP3842534A4 (en) NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID AND METHOD OF USE THEREOF
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
EP3156055A4 (en) Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof
EP3903786A4 (en) NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION TO INCREASE ANTI-CANCER ACTIVITY
WO2016068453A8 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
WO2017105881A8 (en) Deuterated compounds for treating pain
EP3412286A4 (en) TAXOL MEDICINAL PRODUCT AND PHARMACEUTICAL PREPARATION, METHOD OF MANUFACTURING THEREOF AND USE THEREOF
EP3181137A4 (en) Pharmaceutical composition for preventing or treating gleevec-resistant leukemia, containing, as active ingredient, ginsenoside f1 or rg3
EP3212640A4 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
EP3162803A4 (en) New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
WO2015001541A3 (en) Pharmaceutical film composition
EP3398608A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER OR CANCER METASTASES WITH PSTL1-PRTEIN AS AN ACTIVE SUBSTANCE
WO2016020408A3 (en) Compounds for preventing ototoxicity
EP3733179A4 (en) PHARMACEUTICAL PREPARATION WITH A PYRIDYLAMINOACETIC ACID

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16830674

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018503571

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016830674

Country of ref document: EP